MedPath

Prospective Study: Assessing Epicardial Adipose Tissue as a Risk Factor for Major Adverse Cardiovascular Events

Not yet recruiting
Conditions
Other specified disorders of arteries and arterioles,
Registration Number
CTRI/2023/09/057294
Lead Sponsor
Dr Basavaraj GS
Brief Summary

This prospective observational study in Indiafocuses on patients undergoing CT angiography as per the standard ofcare will be screened and enrolled in the study after obtaining informedconsent. The study aims to delineate the influence of EAT volume measured by CTin patients undergoing coronary angiogram and MACE events.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
1812
Inclusion Criteria
  • Adults (Age > 18 years) undergoing CTCA 2.
  • Either sex 3.
  • Consenting to participate 4.
  • Willing for remote monitoring / follow up.
Exclusion Criteria
  • Pregnancy 2.
  • CHF – Stage D 3.
  • Known active malignancy 4.
  • Known CKD stage 5 or Child Pugh C 5.
  • Known Hepatitis B / Hepatitis C 6.
  • HIV and/or ART exposure 7.
  • Endocrinological diseases which might affect the EAT – Cushing’s Syndrome, Acromegaly, Hyperparathyroidism, Pituitary pathologies on medications or hormone supplements, Addison’s disease,Graves’ disease.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
volume determined by CT and MACE events reported in patients undergoing elective coronary angiogram3 years
1.association between the EAT3 years
Secondary Outcome Measures
NameTimeMethod
the correlation between patient’s volume of EAT andprior Coronary artery disease (CAD)

Trial Locations

Locations (1)

Narayana institute of cardiac science

🇮🇳

Bangalore, KARNATAKA, India

Narayana institute of cardiac science
🇮🇳Bangalore, KARNATAKA, India
Dr Basavaraj GS
Principal investigator
9816038562
basavaraj.gs.dr@narayanahealth.org

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.